cytochrome P450 family 4 subfamily F member 36, pseudogeneGenealiases: []
Q-omics provides the consensus-scored CYP4F36P profile across patient tissues and cancer cell-line models. CYP4F36P expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, CYP4F36P is differentially expressed in 2, with the highest sampling consensus in CHOL. Additionally, CYP4F36P RNA expression shows 6,373 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight CESC, CHOL, and STAD as cancer lineages where CYP4F36P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CYP4F36P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CYP4F36P survival associations across molecular data types. CYP4F36P RNA expression shows survival associations in the most cancer types (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CYP4F36P RNA expression–survival associations across cancer types. High CYP4F36P expression shows unfavorable associations in CESC, STAD, UCEC, PCPG and SKCM, but favorable associations in HNSC. The CESC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .006). Together, the overview and detailed table identify CESC as the clearest survival context for CYP4F36P RNA expression.
This table summarizes CYP4F36P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in CHOL for RNA.
This table ranks reproducible tumor–normal expression differences for CYP4F36P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CYP4F36P shows lower tumor expression in CHOL and KIRC. The CHOL box plot shows higher CYP4F36P RNA expression in normal versus tumor tissue (log2 FC = −0.356, t-test p < 0.001).
This table shows molecular features associated with CYP4F36P in patient tissues and cancer cell lines. In patient samples, CYP4F36P shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
